arrow
R

Robin L. Jones

The Royal Marsden NHS Foundation Trust
H指数:92
被引数:3.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pre-diagnostic route reported by patients with sarcoma from the Netherlands, the UK, Australia and New Zealand: early detection challenges for general practitioners - an international observational cohort study

荷兰、英国、澳大利亚和新西兰肉瘤患者的诊断前途径报告:全科医生面临的早期检测挑战——一项国际观察性队列研究

2026-05-040
PRE
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study

Tazemetostat,一种EZH2抑制剂,在携带SWI/SNF突变的实体瘤中的II期篮式研究

2026-03-250
OAAI
Genomic Landscape of Myoepithelial Carcinoma Tumors

肌上皮癌肿瘤的基因组景观

2026-03-150
PRE
Health-related quality of life in patients with advanced soft tissue sarcoma receiving first-line palliative chemotherapy (HOLISTIC): longitudinal results from a prospective, observational cohort study

晚期软组织肉瘤患者接受一线姑息性化疗的健康相关生活质量(HOLISTIC):一项前瞻性、观察性队列研究的纵向结果

2025-10-160
OAAI
A novel risk score after neoadjuvant imatinib predicts relapse-free survival in patients with gastrointestinal stromal tumours (GIST)

一种新型辅助伊马替尼治疗后的风险评分可预测胃肠道间质瘤(GIST)患者的无复发生存期

2025-09-210
PREAI
Corrigendum to ‘Robotic MRI/CT Guided Multiregional ‘smart’ Biopsy for Characterization of Tumor Heterogeneity: A Prospective Development Study’ [Acad Radiol 32/2 (2025) 1100-1107]

勘误:‘Robotic MRI/CT Guided Multiregional ‘smart’ Biopsy for Characterization of Tumor Heterogeneity: A Prospective Development Study’ [Acad Radiol 32/2 (2025) 1100-1107]

2025-07-110
OAAI
Double burden: financial toxicity in patients with advanced soft tissue sarcoma at the start of first-line palliative chemotherapy: baseline data from the HOLISTIC study

双重负担:接受一线姑息化疗的晚期软组织肉瘤患者的财务毒性:HOLISTIC研究基线数据

2025-02-270
OA
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma

SaLudo: lurbinectedin加阿霉素作为平滑肌肉瘤一线治疗的随机IIb/III期研究

2025-02-110
OAAI